MeiraGTx's competitive advantage lies in its end-to-end in-house manufacturing with 5 facilities globally, including two licensed for GMP viral vector production. In 2025, the company announced a strategic collaboration with Hologen including a $200 million cash upfront payment and formation of a joint venture with $230 million in committed capital.
Cyborg Score Rationale
MeiraGTx receives "Strong Buy" consensus from analysts with a 12-month price target of $25.67, representing 197% upside potential. The company has multiple late-stage programs and significant partnership validation, though faces typical clinical-stage biotech execution risks.
Top Insights
AAV2-hAQP1 for radiation-induced xerostomia gained FDA RMAT designation in December 2024, with Phase 2 pivotal trial alignment for potential BLA filing
AAV-GAD for Parkinson's disease showed promising Phase 1/2 results with significant improvements in motor scores and quality of life measures
$430 million Hologen collaboration focuses on neuro-AI platform for CNS drug development in neurodegenerative and neuropsychiatric diseases